← FDA DRUG APPROVALS

FDA ANDA · ANDA062758

ERYZOLE

Sponsor: ALRA

APPLICATION
ANDA062758
TYPE
ANDA
ORIGINAL APPROVAL
1988-06-15
LATEST ACTION
1996-02-07
ROUTE
ORAL
DOSAGE FORM
GRANULE
MARKETING STATUS
Discontinued

Products

ERYZOLEDiscontinued
ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE/5ML, SULFISOXAZOLE ACETYL EQ 600MG BASE/5ML · GRANULE · ORAL

Approval history

1996-02-07Manufacturing (CMC) · Supplement 8AP
1991-10-28Manufacturing (CMC) · Supplement 7AP
1989-03-03Manufacturing (CMC) · Supplement 2AP
1988-11-03Manufacturing (CMC) · Supplement 1AP
1988-06-15OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →